- Home
- ALGS vs MRSN Comparison
ALGS vs MRSN Comparison
Compare ALGS & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- MRSN
- Stock Information
- Founded
- ALGS 2018
- MRSN 2001
- Country
- ALGS United States
- MRSN United States
- Employees
- ALGS N/A
- MRSN N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- MRSN Health Care
- Exchange
- ALGS Nasdaq
- MRSN Nasdaq
- Market Cap
- ALGS 36.0M
- MRSN 40.7M
- IPO Year
- ALGS 2020
- MRSN 2017
- Fundamental
- Price
- ALGS $7.14
- MRSN $0.33
- Analyst Decision
- ALGS Strong Buy
- MRSN Strong Buy
- Analyst Count
- ALGS 1
- MRSN 5
- Target Price
- ALGS $70.00
- MRSN $5.75
- AVG Volume (30 Days)
- ALGS 135.0K
- MRSN 2.0M
- Earning Date
- ALGS 08-05-2025
- MRSN 08-12-2025
- Dividend Yield
- ALGS N/A
- MRSN N/A
- EPS Growth
- ALGS N/A
- MRSN N/A
- EPS
- ALGS N/A
- MRSN N/A
- Revenue
- ALGS $3,270,000.00
- MRSN $34,006,000.00
- Revenue This Year
- ALGS N/A
- MRSN N/A
- Revenue Next Year
- ALGS $51.55
- MRSN $1.30
- P/E Ratio
- ALGS N/A
- MRSN N/A
- Revenue Growth
- ALGS N/A
- MRSN N/A
- 52 Week Low
- ALGS $3.76
- MRSN $0.26
- 52 Week High
- ALGS $46.80
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- ALGS 50.99
- MRSN 41.92
- Support Level
- ALGS $7.11
- MRSN $0.33
- Resistance Level
- ALGS $8.66
- MRSN $0.37
- Average True Range (ATR)
- ALGS 0.88
- MRSN 0.03
- MACD
- ALGS -0.02
- MRSN -0.00
- Stochastic Oscillator
- ALGS 38.79
- MRSN 1.24
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.